iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/37059811/
Inflammation in multiple sclerosis: consequences for remyelination and disease progression - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May;19(5):305-320.
doi: 10.1038/s41582-023-00801-6. Epub 2023 Apr 14.

Inflammation in multiple sclerosis: consequences for remyelination and disease progression

Luisa Klotz  1 , Jack Antel  2 , Tanja Kuhlmann  3   4
Affiliations
Review

Inflammation in multiple sclerosis: consequences for remyelination and disease progression

Luisa Klotz et al. Nat Rev Neurol. 2023 May.

Abstract

Despite the large number of immunomodulatory or immunosuppressive treatments available to treat relapsing-remitting multiple sclerosis (MS), treatment of the progressive phase of the disease has not yet been achieved. This lack of successful treatment approaches is caused by our poor understanding of the mechanisms driving disease progression. Emerging concepts suggest that a combination of persisting focal and diffuse inflammation within the CNS and a gradual failure of compensatory mechanisms, including remyelination, result in disease progression. Therefore, promotion of remyelination presents a promising intervention approach. However, despite our increasing knowledge regarding the cellular and molecular mechanisms regulating remyelination in animal models, therapeutic increases in remyelination remain an unmet need in MS, which suggests that mechanisms of remyelination and remyelination failure differ fundamentally between humans and demyelinating animal models. New and emerging technologies now allow us to investigate the cellular and molecular mechanisms underlying remyelination failure in human tissue samples in an unprecedented way. The aim of this Review is to summarize our current knowledge regarding mechanisms of remyelination and remyelination failure in MS and in animal models of the disease, identify open questions, challenge existing concepts, and discuss strategies to overcome the translational roadblock in the field of remyelination-promoting therapies.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stampanoni Bassi, M., Iezzi, E. & Centonze, D. Multiple sclerosis: inflammation, autoimmunity and plasticity. Handb. Clin. Neurol. 184, 457–470 (2022). - PubMed - DOI
    1. Dobson, R. & Giovannoni, G. Multiple sclerosis — a review. Eur. J. Neurol. 26, 27–40 (2019). - PubMed - DOI
    1. Ontaneda, D., Tallantyre, E., Kalincik, T., Planchon, S. M. & Evangelou, N. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurol. 18, 973–980 (2019). - PubMed - DOI
    1. He, A. et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 19, 307–316 (2020). - PubMed - DOI
    1. Huntemann, N. et al. Failed, interrupted, or inconclusive trials on neuroprotective and neuroregenerative treatment strategies in multiple sclerosis: update 2015–2020. Drugs 81, 1031–1063 (2021). - PubMed - PMC - DOI

Publication types

LinkOut - more resources